{"filing":{"accession_number":"0001999371-26-013429","cik":"0000842023","ticker":"TECH","company_name":"BIO-TECHNE Corp","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tech-8k_062526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/tech-8k_062526.htm"},"events":[{"id":13739,"run_id":12204,"accession_number":"0001999371-26-013429","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Bio-Techne and Merck KGaA executed a definitive Agreement and Plan of Merger on June 25, 2026, with Merck KGaA acquiring Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion. This is a material acquisition disclosed via joint press release, with expected closing by late 2026 or early 2027, subject to customary closing conditions and shareholder approval.","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10966,"accession_number":"0001999371-26-013429","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Bio-Techne and Merck KGaA executed a definitive Agreement and Plan of Merger on June 25, 2026, with Merck KGaA acquiring Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion. This is a material acquisition disclosed via joint press release, with expected closing by late 2026 or early 2027, subject to customary closing conditions and shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:22:37.627353+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10966,"accession_number":"0001999371-26-013429","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Bio-Techne and Merck KGaA executed a definitive Agreement and Plan of Merger on June 25, 2026, with Merck KGaA acquiring Bio-Techne for $73 per share in cash, representing an enterprise value of $11.3 billion. This is a material acquisition disclosed via joint press release, with expected closing by late 2026 or early 2027, subject to customary closing conditions and shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:22:37.627353+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-06-25"}]}